- £172.57m
- £185.35m
- £0.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 289.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.64% | ||
| Return on Equity | n/a | ||
| Operating Margin | -1692.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.2 | 0.46 | 0.34 | 0.27 | 0.51 | 1.5 | n/a | 25.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
4basebio PLC is a United Kingdom-based biotechnology company. The Company is focused on life sciences and in particular the development of synthetic Deoxyribonucleic acid (DNA) and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for cell and gene therapies and vaccines. It is engaged in the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads in patients. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 22nd, 2020
- Public Since
- February 17th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 15,477,395
- Address
- 25 Norman Way, Over, CAMBRIDGE, CB24 5QE
- Web
- https://www.4basebio.com/
- Phone
- +44 1223967943
- Auditors
- Crowe U.K. LLP
Latest News for 4BB
Upcoming Events for 4BB
Full Year 2024 4Basebio PLC Earnings Release
4Basebio PLC Annual Shareholders Meeting
Similar to 4BB
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 18:00 UTC, shares in 4Basebio are trading at 1,115.00p. This share price information is delayed by 15 minutes.
Shares in 4Basebio last closed at 1,115.00p and the price had moved by +31.18% over the past 365 days. In terms of relative price strength the 4Basebio share price has outperformed the FTSE All Share Index by +17.37% over the past year.
The overall consensus recommendation for 4Basebio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out more4Basebio does not currently pay a dividend.
4Basebio does not currently pay a dividend.
4Basebio does not currently pay a dividend.
To buy shares in 4Basebio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1,115.00p, shares in 4Basebio had a market capitalisation of £172.57m.
Here are the trading details for 4Basebio:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: 4BB
Based on an overall assessment of its quality, value and momentum 4Basebio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 4Basebio is 1,800.00p. That is 61.43% above the last closing price of 1,115.00p.
Analysts covering 4Basebio currently have a consensus Earnings Per Share (EPS) forecast of -£0.80 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4Basebio. Over the past six months, its share price has underperformed the FTSE All Share Index by -25.96%.
As of the last closing price of 1,115.00p, shares in 4Basebio were trading -17.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 4Basebio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1,115.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on 4Basebio's directors